Cognititve Therapy Halves Risk of Second Suicide Attempt – JAMA Tue, 6 Sep 2005 A study tested the effect of cognitive therapy in reducing the risk of a second suicide attempt by following 120 people who had attempted suicide. They were followed for 18 months–far longer than drug trials. According…
Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…
Columbia Journalism Review–The Complicity of the Media in Drug Marketing Wed, 27 Jul 2005 An excellent article in the Columbia Journalism Review examines pharmaceutical industry hype and the media’s role in helping that industry create false impressions about the safety and benefits of newly marketed drugs: “stories trumpeting new drugs…
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Pharmaceutical industry corrupt practices are in evidence again, and again, and again.
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail.
A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater
risks of harm than adverse effect reports from clinical trial data reveal.
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
The Times’ humorous profile of JAMA’s editor attempts to trivialize the threat to public health when journals fail to maintain the integrity of science-based medicine.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
